aGvHD: Looking at a 2-6 month approval (priority review) and if successful launch early next year. Looking at a confirmatory study in high risk adults (targeting 50% of the adult market).
ARDS: Wish to replicate results for younger COVID patients; plus other causes of ARDS such as influenza and bacterial pneumonia.
aGvHD: Looking at a 2-6 month approval (priority review) and if...
-
- There are more pages in this discussion • 154 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.0¢ |
Change
-0.010(1.01%) |
Mkt cap ! $1.118B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | 98.0¢ | $4.720M | 4.751M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 171759 | 98.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.0¢ | 16000 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |